Psychedelic Invest is excited to announce that we’ve added 7 new companies to the Psychedelic Invest Index – making us fully up to date on all recent listings.
The Psychedelic Invest Index, the first-ever to track the entire public sector of the psychedelic market, now features:
- Tryp Therapeutics Inc (TRYP)
- BetterLife Pharma Inc. (BETR)
- Mindset Pharma Inc. (MSET)
- Entheon Biomedical Corp. (ENBI)
- CYBIN INC. (CYBN)
- NeonMind Biosciences Inc (NEON)
- Novamind Inc (NM)
The recent additions have been made effective, or otherwise backdated, to January 1, 2021. In total, the index now comprises 41 constituents.
In July of 2020, the index launched with only 22 constituents. This means that in just over 6 months, the public psychedelic sector has nearly doubled, reflecting just how quickly the psychedelic public sector is growing.
Since the rebalancing on January 1, 2020, the Psychedelic Invest Index is up 6.55% with an average 10-day volume of $480.17 million.The Psychedelic Invest Index aims to aid investors looking to gain exposure and transparency to the burgeoning psychedelic market. Look out for further updates and more deep dive analysis in the month ahead.